---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-035987"
form_type: "8-K"
ticker: null
cik: "0001403708"
company_name: "Evoke Pharma Inc"
filed_at: "2024-03-25T23:59:59+00:00"
generated_at: "2026-06-04T08:24:48.777744+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Evoke Pharma amends Series B/C warrants to accelerate vesting, allow pre-funded warrants

## Summary
- Series C warrants become exercisable for up to 3x Series B shares exercised before March 27, 2024 deadline.
- After deadline, remaining Series B exercises trigger one-for-one vesting of Series C warrants.
- Holders may elect pre-funded warrants at exercise price of $0.6799 per share instead of common stock.
- No change to total number of warrant shares underlying each series.
- Company will allow other holders to enter identical amendment.

## SEC filing metadata
- accession: 0000950170-24-035987
- form_type: 8-K
- cik: 0001403708
- company_name: Evoke Pharma Inc
- filed_at: 2024-03-25T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1403708/000095017024035987/0000950170-24-035987-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1403708/000095017024035987/evok-20240325.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-035987
- JSON: https://secwatch.observer/filing/0000950170-24-035987.json
- Plain text: https://secwatch.observer/filing/0000950170-24-035987.txt

## Key facts
- Material Agreements
  Evoke Pharma Inc amended Warrant Amendment with certain holders of its outstanding Series A Warrants, Series B Warrants, and Series C Warrants (effective 2024-03-25).
  - Action: amendment
  - Counterparty: certain holders of its outstanding Series A Warrants, Series B Warrants, and Series C Warrants
  - Effective: 2024-03-25
  source text: On March 25, 2024, Evoke Pharma, Inc. (the “Company”) entered into an amendment (the “Warrant Amendment”) with certain holders (each, a “Holder”) of its outstanding Series A Warrants to purchase shares of common stock (the “Series A Warrants”), Series B Warrants to purchase shares of common stock (the “Series B Warrants”), and Series C Warrants to purchase shares of common stock (the “Series C Warrants”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1403708/000095017024035987/0000950170-24-035987-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.